EUCTR2015-004318-14-DE进行中（未招募）1 期
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction
Prothena Therapeutics Limited0 个研究点目标入组 129 人开始时间: 2015年11月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age =18 years
- •2. Confirmed diagnosis of systemic AL amyloidosis by the following:
- •o Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance
- •o Confirmatory electron microscopy OR immunohistochemistry OR mass spectrometry of AL amyloidosis
- •3. If the subject meets any of the following criteria, confirm diagnosis of AL amyloidosis by mass spectrometry OR immunoelectron microscopy of amyloid material in tissue biopsy:
- •o Is black or African American
- •o Is over 75 years of age (at time of diagnosis) with concurrent monoclonal gammopathy
- •o Has a history of familial amyloidosis and has concurrent monoclonal gammopathy
- •o If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc DPD; Rapezzi et al, 2011), hydroxymethylenediphosphonate (99mTc HMDP; Galat et al, 2015), or pyrophosphate (99mTc PYP; Bokhari et al, 2013) scintigraphy
- •4. Cardiac involvement as defined by BOTH of the following:
- •o Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure
- •o Either an endomyocardial biopsy demonstrating AL amyloidosis OR an echocardiogram demonstrating a mean left ventricular wall thickness at diastole >12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening
- •5. NT-proBNP =650 pg/mL and =5000 pg/mL (i.e., =76.7 pmol/L and =590 pmol/L)
- •6. Received at least one prior systemic chemotherapeutic regimen, which may include stem cell transplant, for AL amyloidosis
- •7. Achieved at least a partial hematologic response to a first-line therapy resulting in a stable hematologic condition not currently requiring additional active treatment against the plasma cell dyscrasia component of their AL disease
- •8. Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:
- •o Absolute neutrophil count (ANC) =1.0 × 109/L
- •o Platelet count =75 × 109/L
- •o Hemoglobin =9 g/dL
- •o Total bilirubin =2 × upper limit of normal (ULN)
- •o Aspartate aminotransferase (AST) =3 × ULN
- •o Alanine aminotransferase (ALT) =3 × ULN
- •o Alkaline phosphatase (ALP) =5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
- •o Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- •9. Systolic blood pressure 90-180 mmHg
- •10. Distance walked during each of the two Screening 6-minute walk tests (6MWTs) is >100 meters and <600 meters
- •11. Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
- •12. Male subjects must be surgica
排除标准
- •Subjects must not meet any of the following criteria:
- •1. Diagnosis of non-AL amyloidosis
- •2. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma
- •3. Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject's ability to safely receive treatment or complete study assessments
- •4. Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit
- •5. Severe valvular stenosis (e.g. aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease
- •6. ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:
- •o First degree atrioventricular (AV) block
- •o Second degree AV block Type 1 (Mobitz Type 1/Wenckebach type)
- •o Right or left bundle branch block
- •o Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., >110 bpm] ventricular rate is not allowed [determined by an average of three beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG])
- •7. Has not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse Events [CTCAE] =Grade 2) from the clinically significant toxic effects of prior anticancer therapy. Exception: subjects with prior bortezomib treatment may have CTCAE Grade 2 neuropathy.
- •8. Received any of the following within the specified time frame prior to the Month 1-Day 1 Visit:
- •o Oral or intravenous antibiotics, antifungals, or antivirals within 1 week, with the exception of prophylactic oral agents. Note: In the event that a subject requires the chronic use of antivirals, Medical Monitor permission is required for entry into the study.
- •o Hematopoietic growth factors, transfusions of blood or blood products within 1 week
- •o Chemotherapy, radiotherapy, or other plasma cell directed therapy within 6 months
- •o ASCT within 12 months
- •o Major surgery within 4 weeks
- •o Planned major surgery or organ transplant during the study
- •o Any other investigational agent within 4 weeks
- •o Prior treatment with NEOD001, 11-1F4, anti-serum amyloid P (SAP) antibody (exception: allowed as part of established diagnostic procedures such as SAP scintigraphy), or other investigational treatment directed at amyloid
- •o Doxycycline within 6 weeks
- •9. Active malignancy with the exception of any of the following:
- •o Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer
- •o Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for =2 years
- •o Low-risk prostate cancer with Gleason score <7 and prostate-specific antigen <10 mg/mL
- •o Any other cancer from which the subject has been disease-free for =2 years
- •10. History of Grade =3 infusion-related adverse events (AEs) or hypersensitivity to another monoclonal antibody
- •11. History of severe allergy to any of the components of NEOD001 such as histidine/L-histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20
- •12. Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infection
- •13. Women who are breastfeeding
- •14. Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject’s risk by p
研究者
相似试验
进行中（未招募）
1 期
A controlled clinical trial to study RM-131 (relamorelin) in patients with vomiting symptoms and diabetic gastroparesisVomiting symptoms in patient with moderate to severe diabetic gastroparesisMedDRA version: 17.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-005623-27-BERhythm Pharmaceuticals, Inc.395
进行中（未招募）
1 期
A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s DiseaseEUCTR2016-000634-21-HUJanssen-Cilag International NV693
进行中（未招募）
1 期
A study to investigate the effects of lumicitabine (JNJ-64041575) in hospitalized adults infected with human metapneumovirusHuman metapneumovirus infectionMedDRA version: 20.0Level: PTClassification code 10066226Term: Metapneumovirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001696-22-SEJanssen-Cilag International NV180
进行中（未招募）
1 期
A Phase 2b study for adults hospitalized with Respiratory Syncytial Virus.MedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsRespiratory Syncytial Virus InfectionEUCTR2016-001653-40-PLJanssen-Cilag International NV216
进行中（未招募）
1 期
A double-blind, placebo-controlled Clinical Trial to evaluate the Safety and Efficacy of JNJ-64304500 in patients with Moderately to Severely Active Crohn’s DiseaseActive Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-000634-21-DEJanssen-Cilag International NV654